Phase 4Not yet recruiting
Using GLP-1 to prevent Post-Transplantation Diabetes Mellitus
- Sponsor
- Radboud universitair medisch centrum Stichting (Academic or other)
- Enrolment
- 100 planned
- Conditions
- Post-transplantation Diabetes Mellitus
- Interventions
- Ozempic 1 mg solution for injection in pre-filled pen; Ozempic 0.5 mg solution for injection in pre-filled pen; Glucose 20 %, oplossing voor infusie; Ozempic 0.25 mg solution for injection in pre-filled pen; GlucaGen Hypokit 1 mg poeder en oplosmiddel voor oplossing voor injectie.
- Ages
- adults, older adults
- Registry
- CTIS2026-525910-77-00
Full record on the EU Clinical Trials Information System
From the registry
Main objective: To assess whether a 3-month course of GLP-1RA can prevent the occurrence of PTDM in a proof-of-concept study in people up to 6 months after receiving kidney transplantation.
Primary outcomes
- The occurrence of PTDM in the first six months after receiving a kidney transplantation
History
Registered